Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers

代谢物 尿 最大值 药代动力学 葡萄糖醛酸化 化学 药理学 粪便 初级代谢物 医学 生物 生物化学 酶 微粒体 古生物学
作者
Yicong Bian,Jian Meng,Sheng Ma,Guangze Li,Yuya Wang,Shaorong Li,Linsheng Liu,Chenrong Huang,Hua Zhang,Dafang Zhong,Liyan Miao
出处
期刊:British Journal of Clinical Pharmacology [Wiley]
卷期号:88 (7): 3307-3320 被引量:1
标识
DOI:10.1111/bcp.15256
摘要

This trial (NCT04013048) investigated the metabolite profiles, mass balance and pharmacokinetics of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.A single dose of 150 mg [14 C]fuzuloparib was administered to five subjects with advanced solid cancers. Blood, urine and faecal samples were collected, analysed for radioactivity and unchanged fuzuloparib, and profiled for metabolites. The safety of the medicine was assessed during the study.The maximum concentrations (Cmax ) of the total radioactivity (TRA) and unchanged fuzuloparib in plasma were 5.39 μg eq./mL and 4.19 μg/mL, respectively, at approximately 4 hours post dose. The exposure (AUC0-t ) of fuzuloparib accounted for 70.7% of the TRA in plasma, and no single metabolite was observed accounting for more than 10% of the plasma TRA. The recovery of TRA in excreta was 103.3 ± 3.8% in 288 hours, including 59.1 ± 9.9% in urine and 44.2 ± 10.8% in faeces. Sixteen metabolites of fuzuloparib were identified, including mono-oxidation (M1), hydrogenation (M2), di-oxidation (M3), trioxidation (M4), glucuronidation (M5, M7, M8) and de-ethylation (M6) products, and there was no specific binding between these metabolites and blood cells. Aliphatic hydroxylated fuzuloparib (M1-1) was the primary metabolite in the excreta, accounting for more than 40% of the dose for subjects. There were no serious adverse events observed in the study.Fuzuloparib was widely metabolized and excreted completely through urine and faeces in subjects with advanced solid cancer. Unchanged fuzuloparib was indicated to be the primary drug-related compound in circulation. [14 C]fuzuloparib was well-tolerated at the study dose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大聪明发布了新的文献求助10
1秒前
小火车发布了新的文献求助10
2秒前
星辰大海的应助被碧蓝梦寒采纳,获得10
2秒前
2秒前
2秒前
可爱的函函的应助被Zzz采纳,获得10
3秒前
yjh完成签到,获得积分10
3秒前
3秒前
Maestro_S的应助被蓝月采纳,获得10
5秒前
7秒前
GTY发布了新的文献求助10
7秒前
7秒前
Bill完成签到,获得积分10
8秒前
9秒前
sheetung完成签到,获得积分10
9秒前
在水一方的应助被whs采纳,获得10
9秒前
9秒前
中中中发布了新的文献求助10
9秒前
顺利代亦发布了新的文献求助10
9秒前
9秒前
思源的应助被害怕的奇异果采纳,获得10
10秒前
完美世界的应助被王泰一采纳,获得10
11秒前
礼拜一发布了新的文献求助10
11秒前
11秒前
顾矜的应助被王泰一采纳,获得10
11秒前
bkagyin的应助被王泰一采纳,获得10
11秒前
科研通AI2S的应助被王泰一采纳,获得10
11秒前
Hello的应助被王泰一采纳,获得10
11秒前
情怀的应助被xmyuan采纳,获得10
12秒前
12秒前
BAEKHYUNLUCKY发布了新的文献求助10
12秒前
12秒前
Owen的应助被Archie采纳,获得10
12秒前
research完成签到,获得积分10
13秒前
Chen发布了新的文献求助10
13秒前
13秒前
Qin的应助被小阿捡子采纳,获得10
13秒前
dr_chou发布了新的文献求助20
13秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172327
求助须知:如何正确求助?哪些是违规求助? 9564990
关于积分的说明 21777687
捐赠科研通 7763968
什么是DOI,文献DOI怎么找? 3431223
关于科研通互助平台的介绍 2555098
邀请新用户注册赠送积分活动 2476246